Samsung Epis Holdings maintains debt-free management in Q1

May 21, 2026, 09:07 am

Samsung Epsis Holdings continued its virtually debt-free management in the first quarter of this year, maintaining a stable financial structure while accelerating investment in new drug development, according to industry and regulatory data released Monday.

The company’s financial soundness, combined with the steady earnings growth of key subsidiary Samsung Bioepis, is fueling expectations that Samsung Group’s biotechnology business is expanding beyond its traditional CDMO (contract development and manufacturing organization) focus into innovative drug development.

According to South Korea’s Financial Supervisory Service, Samsung Epsis Holdings posted a standalone debt ratio of just 0.29% in the first quarter, effectively maintaining a debt-free balance sheet. Its cash and cash equivalents stood at 35 billion won ($25 million), down from 59.8 billion won at the end of last year, which industry observers attributed to increased investment in new drug development projects.

Samsung Epsis Holdings was established last year through a corporate spin-off. Since receiving initial funding support from Samsung Biologics, the holding company has continued investments primarily with internal funds, without relying on dividend income from Samsung Bioepis.

Industry attention has focused on the company’s financial structure as investment in novel therapeutics has accelerated following the spin-off. While Samsung’s biotech business has traditionally grown around Samsung Biologics’ CDMO operations, the group has recently been expanding into higher-value innovative drug development.

Backed by its strong financial position, the company has also widened its external collaboration efforts. Over the past year, Samsung Bioepis and Samsung Epsis Holdings have expanded open innovation partnerships across areas including antibody-drug conjugates (ADCs), obesity therapeutics, and AI-powered drug discovery.

In the ADC segment, the company signed a joint research and development partnership with China-based Frontline Biopharma for oncology drug candidates. In obesity treatment, Samsung Bioepis entered a joint research and licensing agreement with G2GBIO in the first quarter to develop long-acting obesity therapeutics.

For AI-based drug development, the company is jointly developing antibody candidates with Proteina and a research team from Seoul National University. The project has been selected as a national R&D initiative supported by South Korea’s Ministry of Health and Welfare.

The company is also strengthening support for the biotech startup ecosystem through partnerships with organizations including Seoul Bio Hub and China’s Atlatl Innovation Center to identify promising startups.

Meanwhile, Samsung Bioepis continued its earnings growth in the first quarter. Revenue rose 13.6% year-on-year to 454.8 billion won, compared with 400.6 billion won a year earlier. Operating profit increased 12.6% to 144 billion won from 128 billion won during the same period.

Industry analysts said Samsung Bioepis’ stable profit structure is expected to serve as a foundation for expanding investment in innovative drug development going forward.

Samsung Epsis Holdings plans to double its R&D investment this year compared with the previous year. At the company’s shareholder meeting in March, CEO Kim Kyung-ah said the company aims to advance at least one drug candidate into pivotal clinical trials every year. CFO Vice President Kim Hyung-joon added that the company plans to invest more than 400 billion won annually in research and development.

Despite its current reliance on internal funding, the company has also left open the possibility of external financing as clinical programs advance into later stages, where development costs typically increase significantly. Industry officials noted that the company’s current financial structure provides ample room for future fundraising if needed.

#Samsung Epis Holdings #Samsung Bioepis #ADC #obesity treatment #AI drug development